

Bivalirudin (Trifluoroacetate)

Catalog No: tcsc1433



Available Sizes

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

128270-60-0

Formula:

$C_{100}H_{138}DF_3N_{24}O_{35}$

Pathway:

Metabolic Enzyme/Protease

Target:

Thrombin

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 31 mg/mL (13.51 mM)

Observed Molecular Weight:

2295.31

Product Description

Bivalirudin Trifluoroacetate is a synthetic 20 residue peptide which reversibly inhibits thrombin.


IC50 Value:

Target: thrombin

in vitro: Eptifibatid (8 mg/mL) added together with a low (70 ng/mL) concentration of bivalirudin (a direct thrombin inhibitor) effectively (approximately 90%) reduced platelet aggregation induced by thrombin (0.2 U/mL) [1]. In thrombin generation assay (TGA), bivalirudin had no effect on these parameters up to 10 μ mol/l [2]. Bivalirudin-facilitated binding of MPO to BAEC resulted also in functional changes in terms of increased NO consumption as well as enhanced MPO-mediated redox modifications [3].

in vivo: The use of bivalirudin prevented further increase in antiheparin/PF4 antibody IgG levels in rats [4]. Three animals in the 500-mg/kg/24 h group, and 7 animals in the 2000-mg/kg/24 h group in the toxicokinetic assessment phase of the study were found dead or euthanized in extremis (following blood sampling). Plasma concentrations of bivalirudin appeared to be linear and dose independent [5].

Clinical trial: Antithrombotic Effects of Ticagrelor Versus Clopidogrel . Phase 4



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!